A potential hypothesis for 2019-nCoV infection therapy through delivery of
recombinant ACE2 by red blood cell-hitchhiking
#MMPMID34963881
Aghili ZS
; Mirzaei SA
; Banitalebi-Dehkordi M
J Biol Res (Thessalon)
2020[Dec]; 27
(?): 17
PMID34963881
show ga
A novel infectious disease, caused by 2019 Novel Coronavirus (2019-nCoV) is
responsible for the recent outbreak of severe respiratory disease. The 2019-nCoV
spread rapidly and reaching epidemic proportions in many countries of the world.
ACE2 was identified as a key receptor for 2019-nCoV infections. Excessive form of
soluble ACE2 rescues cellular ACE2 activity which has a protective role in acute
lung failure and neutralizes the virus. The short half-life of ACE2 is a major
limitation to its practical application. Nanoparticle-based drug delivery systems
are one of the most widely investigated approaches for developing novel therapies
for a variety of diseases. Nevertheless, nanoparticles suffer from the rapid
removal from the bloodstream by the reticuloendothelial system (RES). A
noncovalent attachment of nanoparticles to RBCs increases their half-life in
blood and allows transient accumulation in the lungs, while decreases their
uptake by the liver and spleen. Connecting the recombinant ACE2 into the surface
of nanoparticles that were attached to RBCs can be a potential therapeutic
approach for 2019-nCoV infection through increasing their lung targeting to
naturalize the virus and also acting as a bioreactor in the blood circulation to
decrease serum level of Angiotensin II and protects lungs from injury/ARDS.
free
free
free
